Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas.
about
Iodine-125 brachytherapy for brain tumours--a reviewGliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients.A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastomaRadiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesisStratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.The radiation oncologist's perspective on stereotactic radiosurgery.Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy.Controversies concerning the application of brachytherapy in central nervous system tumors.The role of brachytherapy in the treatment of glioblastoma multiforme.Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme.
P2860
Q27011501-859649F1-5D8F-4613-B9DF-2566A9BB9CB6Q31035468-CB439EF7-0473-444F-8019-719F128920B8Q33356349-3C050BFD-93F3-4E1A-B8C0-B5A8A32B7F11Q33378699-FC11D155-0E2C-4B28-ADF8-5D90573F5EA5Q33708309-25083101-9A33-4B38-958F-C7B95F5084E6Q33779136-BF5DBD82-7BE4-4365-B75D-B48FC7755BCFQ34145860-502F74A8-EC98-45B7-A7EF-F5D00E1E40B7Q34260758-C905E48F-7A81-4D6A-9FDF-A88A764B2A80Q35076562-DEEF3ED0-D7AB-4AF0-861C-7F931E135377Q36257231-E3C3FC4A-BAA0-41D4-9846-77C511FBD4E6Q37643520-B7439C65-D624-40CD-B937-0B523B3654E5Q38834847-02151EB3-00FE-49FC-8004-426A5D6EC949Q42749632-4DF3B45D-3DF4-42ED-BA73-61C4E5DAE942
P2860
Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Use of the RTOG recursive part ...... reatment of malignant gliomas.
@en
Use of the RTOG recursive part ...... reatment of malignant gliomas.
@nl
type
label
Use of the RTOG recursive part ...... reatment of malignant gliomas.
@en
Use of the RTOG recursive part ...... reatment of malignant gliomas.
@nl
prefLabel
Use of the RTOG recursive part ...... reatment of malignant gliomas.
@en
Use of the RTOG recursive part ...... reatment of malignant gliomas.
@nl
P2093
P1476
Use of the RTOG recursive part ...... reatment of malignant gliomas.
@en
P2093
Fontanesi J
Tekyi-Mensah S
Videtic GM
Zamorano L
P304
P356
10.1016/S0360-3016(99)00244-8
P407
P577
1999-10-01T00:00:00Z